(E)-2-fluoro-4'-methoxystilbene

• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 二苯乙烯类
• 英文名称: (E)-2-fluoro-4'-methoxystilbene
• 英文别名: NF-kB Activation Inhibitor IV；1-fluoro-2-[(E)-2-(4-methoxyphenyl)ethenyl]benzene
• 化学式: C₁₅H₁₃FO
• 分子量: 228.266
• InChiKey: ILVFNAZMSMNXJG-RMKNXTFCSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  17
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  9.2
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  (E)-2-fluoro-4'-methoxystilbene 在 palladium 10% on activated carbon 、 氢气 作用下， 以 乙醇 为溶剂， 反应 3.0h， 生成 1-fluoro-2-(4-methoxyphenethyl)benzene
  参考文献：
  名称：

  Identification of dihydrostilbenes in Pholidota chinensis as a new scaffold for GABAA receptor modulators

  摘要：

  A dichloromethane extract of stems and roots of Pholidota chinensis (Orchidaceae) enhanced GABA-induced chloride currents (I-GABA) by 132.75 +/- 36.69% when tested at 100 mu g/mL in a two-micro-electrode voltage clamp assay, on Xenopus laevis oocytes expressing recombinant alpha(1)beta(2)gamma S-2 GABA(A) receptors. By means of an HPLC-based activity profiling approach, the three structurally related stilbenoids coelonin (1), batatasin III (2), and pholidotol D (3) were identified in the active fractions of the extract. Dihydrostilbene 2 enhanced I-GABA by 1512.19 +/- 176.47% at 300 mu M, with an EC50 of 52.51 +/- 16.96 mu M, while compounds 1 and 3 showed much lower activity. The relevance of conformational flexibility for receptor modulation by stilbenoids was confirmed with a series of 13 commercially available stilbenes and their corresponding semisynthetic dihydro derivatives. Dihydrostilbenes showed higher activity in the oocyte assay than their corresponding stilbenes. The dihydro derivatives of tetramethoxy-piceatannol (12) and pterostilbene (20) were the most active among these derivatives, but they showed lower efficiencies than compound 2. Batatasin III (2) showed high efficiency but no significant subunit specificity when tested on the receptor subtypes alpha(1)beta(2)gamma(2)s, alpha(2)beta(2)gamma(2)s, alpha(3)beta(2)gamma(2)s, alpha(4)beta(2)gamma(2)s, alpha(5)beta(2)gamma(2)s, alpha(1)beta(1)gamma(2)s, and alpha(1)beta(3)gamma(2)s. Dihydrostilbenes represent a new scaffold for GABAA receptor modulators. (C) 2014 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2014.01.008
• 作为产物：
  描述：

  4-甲氧基苯基磷酸二乙酯 、 2-氟苯甲醛 生成 (E)-2-fluoro-4'-methoxystilbene
  参考文献：
  名称：

  由取代的抗氧化剂的Nrf2信号的激活反式茋

  摘要：

  Nrf2是cap'n'collar转录因子家族的成员，是II期排毒和抗氧化基因以及抗炎和神经保护基因的主要调节剂。在许多慢性疾病中炎症和氧化应激的重要性支持了抗氧化剂Nrf2信号转导可能具有治疗潜力的概念。许多Nrf2激活剂已进入临床试验。Nrf2与它的结合伴侣Keap1结合存在于胞质溶胶中，Keap1是一种富含硫醇的氧化还原传感蛋白。响应于氧化和亲电子应力，Keap1的选定半胱氨酸残基被修饰，从而将Keap1锁定在Nrf2-Keap1复合物中，并使新合成的Nrf2进入细胞核。激活Nrf2的多种化学物质，包括多种天然产物，是亲电试剂，通常通过迈克尔加成来修饰Keap1，从而导致Nrf2激活。作为Keap1的亲电子共价修饰剂的Nrf2活化剂的设计，一个需要关注的问题是选择性问题。在本研究中，替代反式斯蒂芬苯酯被鉴定为Nrf2的激活剂。这些Nrf2激活剂不是高度亲电的，因此不太可能通过Keap

  DOI：

  10.1016/j.bmc.2017.01.005

文献信息

• Substituted CIS- and trans-stilbenes as therapeutic agents
  申请人：Vander Jagt David L.

  公开号：US20070249647A1

  公开（公告）日：2007-10-25

  The present invention relates to method(s) of treating a subject afflicted with cancer or a precancerous condition, an inflammatory disease or condition, and/or stroke or other ischemic disease or condition, the method comprising administering to the subject or patient in need a composition comprising a therapeutically effective amount of a substituted cis or trans-stilbene.

  本发明涉及治疗患有癌症或癌前病变、炎症性疾病或病情以及中风或其他缺血性疾病或病情的方法，该方法包括向需要的受试者或患者施用含有一定治疗有效量的取代的顺式或反式-芪的组合物。
• [EN] COSMETIC COMPOSITIONS AND METHODS OF USE<br/>[FR] COMPOSITIONS COSMÉTIQUES ET PROCÉDÉS D'UTILISATION
  申请人：STC UNM

  公开号：WO2020112998A1

  公开（公告）日：2020-06-04

  The present invention relates to substituted stilbenes and dienones which exhibit unexpected dual activity, as inhibitors of NFKB and as agonists (activators) ofNrf2. In particular, these compounds show dual activity and it has been discovered that these compounds are particularly useful in the treatment of certain cosmetic applications and in rejuvenating and beautifying skin and other keratinous tissue of a subject in need. Cosmetic compositions and methods of using said compositions in combination with other components are disclosed herein.

  本发明涉及替代的stilbenes和dienones，表现出意外的双重活性，作为NFKB的抑制剂和Nrf2的激动剂。特别是，这些化合物展现了双重活性，已经发现这些化合物在治疗某些化妆品应用以及在使需要的主体的皮肤和其他角质组织恢复活力和美化方面特别有用。本文披露了化妆品组合物以及使用所述组合物与其他成分结合的方法。
• Pretargeted activatable cell penetrating peptide with intracellularly releasable prodrug
  申请人：The Regents of the University of California

  公开号：US10029017B2

  公开（公告）日：2018-07-24

  Disclosed herein, the invention pertains to methods and compositions that find use in treatment, diagnosis, prognosis and characterization of disease and disease samples based on the ability of a disease sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is a pre-targeting moiety; M is a macromolecular carrier, C is a detectable moiety; and T is a compound for delivery to a target, including for example a therapeutic compound.

  在此公开的本发明涉及根据疾病样本裂解本发明的 MTS 分子的能力用于疾病和疾病样本的治疗、诊断、预后和表征的方法和组合物。本发明的 MTS 分子具有如本文所公开的式，其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 和 Y 是连接体；P 是预靶向分子；M 是大分子载体；C 是可检测分子；T 是用于递送至靶点的化合物，例如包括治疗化合物。
• Personalized protease assay to measure protease activity in neoplasms
  申请人：The Regents of the University of California

  公开号：US10385380B2

  公开（公告）日：2019-08-20

  Disclosed herein, the invention pertains to methods and compositions that find use in diagnostic, prognostic and characterization of neoplasia samples based on the ability of a neoplasia sample to cleave a MTS molecule of the present invention. In some embodiments, a MTS molecule disclosed herein has the formula (A-X-B-C), wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X is a linker; and C is a detectable moiety.

  本发明涉及根据肿瘤样本裂解本发明 MTS 分子的能力，用于诊断、预后和表征肿瘤样本的方法和组合物。在一些实施方案中，本发明公开的 MTS 分子具有式（A-X-B-C），其中 A 是多肽，其序列包括 5 至 9 个连续的酸性氨基酸，其中氨基酸选自天冬氨酸和谷氨酸；B 是多肽，其序列包括 5 至 20 个连续的碱性氨基酸；X 是连接体；C 是可检测分子。
• Tumor radiosensitization with monomethyl auristatin E (MMAE) and derivatives thereof
  申请人：The Regents of the University of California

  公开号：US10596259B2

  公开（公告）日：2020-03-24

  Disclosed herein, the invention pertains to methods and compositions that find use in radiosensitization of tumors and tumor samples based on the ability of a tumor sample to cleave a MTS molecule of the present invention. The MTS molecules of the present invention have a formula as disclosed herein and wherein A is a peptide with a sequence comprising 5 to 9 consecutive acidic amino acids, wherein the amino acids are selected from: aspartates and glutamates; B is a peptide with a sequence comprising 5 to 20 consecutive basic amino acids; X and Y are linkers; P is an optional pre-targeting moiety; M is an optional macromolecular carrier; and T is a radiosensitization agent for delivery to a target, including for example a therapeutic compound.

  本发明涉及根据肿瘤样品裂解本发明MTS分子的能力对肿瘤和肿瘤样品进行放射增敏的方法和组合物。本发明的MTS分子具有如本文所公开的式，其中A是具有包含5至9个连续酸性氨基酸序列的多肽，其中氨基酸选自天冬氨酸和谷氨酸；B是具有包含5至20个连续碱性氨基酸序列的多肽；X和Y是连接体；P是任选的前靶向分子；M是任选的大分子载体；T是用于递送至靶点（例如包括治疗化合物）的放射增敏剂。